VEGFA and lung cancer: Additional studies illuminate azithromycin’s anti-inflammatory and anti-angiogenic properties, as seen in increased TNF receptor type 1 expression in liver cancer cells and reduced vascular endothelial growth factor (VEGF) and VEGF receptor 2 expression in lung cancer models [61,62,63].